Regulatory Myeloid-Cell Dynamics In Asthmatics During Pregnancy

Asthma is one of the most common chronic inflammatory lung diseases among pregnant women. Acute asthma exacerbations during pregnancy negatively impact pregnancy outcomes. As myeloid-derived suppressor cell (MDSC) populations are known regulators of airway inflammation and are important in maternal-fetal tolerance, we investigated if percentages of circulating MDSC subsets correlated with clinical indicators of airway inflammation and maternal-fetal tolerance in a cohort of healthy pregnant (HP), asthmatic pregnant (AP) and well controlled asthmatic pregnant (WCAP) women recruited to the B-WELL Mom study. Reciprocal dynamics of circulating MDSC subsets, with granulocytic MDSCs (Gr-MDSCs) increasing over early pregnancy and declining in late stage pregnancy and the reverse trend with monocytic MDSCs (Mo-MDSCs) were identified; the decline of Mo-MDSCs at Visit 3 of pregnancy was higher in AP/WCAP compared to HP whereas the decline of Gr-MDSCs at late stage pregnancy was lower in AP/WCAP compared to HP. In AP/WCAP, positive correlations were observed between both MDSC subsets during pregnancy and Gr-MDSCs correlated positively with fractional exhaled nitric oxide, a surrogate measure of airway inflammation, during early pregnancy; these relations were not identified in HP subjects. Interestingly, soluble HLA-G as well as indoleamine 2,3 dioxygenase activity, both important in maternal-fetal tolerance, showed positive correlations with MDSCs only in HP and not in AP/WCAP subjects. Our studies suggest that differential myeloid-cell dynamics may serve as biomarkers of maternal-fetal tolerance in AP/WCAP subjects.

Related Concept Videos

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by...
453
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
613
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
495
Asthma-IV: Diagnostic and Management01:30

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.6K